Jessica Menis

Medical Oncologist at University Hospital of Verona

[Giannis Mountzios @g_mountzios]

With #ASCO26 just around the corner, it is my great pleasure to present in the oral abstract session, alongside prominent colleagues and chairs, the intracranial efficacy data of #tarlatamab from #DeLLphi-304 trial, the first data on CNS efficacy of a T-cell engager in #SCLC. Stay tuned!!

📌 Sunday June 1st, 13:15-16:15, Hall D1

#SoMe #LCSM @SclcSMASHERS
@OncoAlert @OncBrothers
@PeerView @PortalOnconews @MedscapeOnc
@VJOncology @ecancer @LungCancerEu @YoungLungCancer @HeSMO_X @HenryDunantGR

[Alona Zer @ZerAlona]

Honoring Dr. Frances Shepherd, as she retires after six decades of advancing lung cancer research and patient care 🫁— a true pioneer, visionary leader, and deeply inspiring physician 🦸‍♀️🏆👸@TonyMok9 @CelineMascaux @karenkellymd

[Stephen V Liu, MD @StephenVLiu]

In this episode of Lung Cancer Considered, the @IASLC podcast, I discuss the current treatment considerations for advanced SCLC with Dr. Raffaele Califano and Dr. Jessica Menis. Listen below for the current state of the art! @caliraf @JessicaMenis

https://t.co/cg8v3B5bxg

[Stephen V Liu, MD @StephenVLiu]

Real world analysis of tarlatamab in SCLC (n=27) @JCOPO_ASCO: RR 18%, PFS 5.9m. Signs of CNS activity: in 14pts with brain mets, 2 CR & 1 PR; in 4pts with no baseline mets, none had new CNS mets. C1D1: CRS in 37%, ICANS in 30%. C1D8, CRS 40%, ICANS 16%.

https://t.co/nNlIBVhOqg

[Jessica Menis @JessicaMenis]

@g_mountzios @myESMO @ElinardouHelena @peters_solange @finn_corinne @HendriksLizza @PrelajArsela @MartinReck2 @NReguart @JordiRemon @HeSMO_X 👏🏻👏🏻👏🏻👏🏻

[Jessica Menis @JessicaMenis]

@g_mountzios @myESMO @NReguart @HLinardou @peters_solange @JordiRemon @HendriksLizza @finn_corinne @PrelajArsela @MartinReck2 Great team 😊

[Giannis Mountzios @g_mountzios]

Farewell to another productive and exceptionally brainstorming @EORTC LCG meeting under the leadership and guidance of @JordiRemon @HendriksLizza @MarianaBrandao0
Huge 🙏 to Rafal Dziadziusco for a wonder honestly n beautiful Gdansk!!
See you all next year in Athens!!!!

[Jordi Remon @JordiRemon]

Great discussions at the EORTC Lung Cancer Group meeting in Gdańsk. A real privilege to work with such a collaborative and forward-thinking community—especially encouraging to see new voices actively contributing to study design and research priorities. You are welcome!! #EORTC

[Giannis Mountzios @g_mountzios]

Best way to start the @EORTC lung cancer group meeting here in #Gdansk with a fascinating symposium focusing on #SCLC with amazing lectures by @bartolomiej @finn_corinne and @NReguart , including a deep dive in SCLC biology

[Jordi Remon @JordiRemon]

Fantastic presentation by Prof Jassem about roles of Pharma / Academia in drug development.
The strength of the EORTC Lung Cancer Group lies in its multidisciplinary to design academic studies with drugs developed by pharma aiming to identify optimal drug for groups of patients

[Jessica Menis @JessicaMenis]

EORTC LCG symposium at the start: amazing lecture of Prof Jacek Jassem
@JordiRemon @HendriksLizza @MarianaBrandao0 @NReguart @g_mountzios @finn_corinne @BenjaminBesseMD @RobertoFerrara_ @paolobironzo @elenaprisciandaro @AnnemarieDing @EORTC @rafaldziadziusko

[Jordi Remon @JordiRemon]

Excited to be in Gdansk for the @EORTC Lung Cancer Group Spring Meeting. Proud to see so many early-career investigators leading discussions, challenging ideas, and shaping the future of thoracic oncology. The next generation is already here. #LungCancer #Oncology #EORTC

[Jarushka Naidoo @DrJNaidoo]

Should we do molec testing on all NSCLCs? Answer: YES @JTOonline
- 82328pts
- 35.1% AGA+ (adeno=45.8% adenosq=40.9% sarcomatoid=29.1% NOS=27.6%, LCC=21.1% sq=6.5%)
- age, sex, region assoc seen

Congrats @Al3ssandroRusso @ChristianRolfo @oncoalert #LCSM
https://t.co/M3bDWxZA7U

[Stephanie Saw @stephanieplsaw]

Our review on targeting MET in EGFRm NSCLC is out in @JTOonline! Always interesting to appreciate the similar challenges we face treating EGFRm lung cancer around the world. Thanks to all my co-authors, academia is much better with friends indeed ☺️

[Jordi Remon @JordiRemon]

Looking forward to EORTC LCG spring meeting:Gdansk 16-18 April hosted by Pr Dziadziuszko & Dr Bandura + Young Early Career Investigators meeting on 16 April led by the fantastic @RobertoFerrara and Dr Prisciandaro. The future of EU🫁 oncology in EU is bright!Stay tuned⭐️⭐️@EORTC

[Jarushka Naidoo @DrJNaidoo]

Congrats to our own @ConorMoloneyOnc & #CarolineKinsella on their great contribution to the new @myesmo handbook:

‘Thoracic Tumours: Essentials for Clinicians’ on immunotherapy resistance in advanced NSCLC

Great work! 🇮🇪
@cancercentreire @cancertrials_ie #LCSM

[Giannis Mountzios @g_mountzios]

impressive data in #SCLC26 on IZA-BREN ( EGFRxHER3 ADC) with ICI surplulimab in 1L ES-SCLC:
➡️ ORR 85-92%! across IZABREN doses
➡️ mDOR =7-8 m
➡️ Discontinuation due to TRAEs only 7.3%

Dawn 🌅 of a carbo-Etop- free 1L treatment in SCLC?
@myESMO @IASLC

[Giannis Mountzios @g_mountzios]

A very moving and emotional opening session here in Copenhagen for #ELCC26 with the two chairs @DrSanjayPopat and @APassaroMD remembering and honoring two leaders that helped shaping modern thoracic oncology, Filippo de Marinis and Masahiro Tsuboi. Their legacy will be always remembered and cherished
@myESMO @IASLC

[Giannis Mountzios @g_mountzios]

#ELCC26 loading!!! ➡️➡️➡️➡️

Ready to meet, interact and connect with great colleagues and friends from around the globe!!
@JessicaMenis @JordiRemon

[Giannis Mountzios @g_mountzios]

👉How do we combine #TKIs with various forms of #radiotherapy in #NSCLC? When should we interrupt or modify their dose?

💡Just out in @ESMO_Open a collaborative effort between @myESMO and @estro with recommendations for #EGFR, #ALK and #BRAF/MEK inhinitors

Happy to have contributed to this practical guide for clinicians

Link to the article: https://t.co/A1SvhgKFXm

#LCSM @IASLC @ASCO
@OncoAlert @OncBrothers
@oncodaily @MedscapeOnc @VJOncology @Peerview
@EGFRResisters @EgfrUk @EGFRmNSCLC
@YoungLungCancer @ALKPositiveinc